Non-regulatory announcement
ONDINE BIOMEDICAL
INC.
("Ondine
Biomedical", "Ondine", or the "Company")
Ondine unveils new research
at SPIE Photonics West
Canadian life sciences company Ondine Biomedical Inc.
(LON: OBI) will present new research at the SPIE
Photonics West conference in San Francisco,
California. The presentation will provide details of an exploratory
study showing that photodisinfection significantly reduces
pathogens in the nose - a reservoir for bacteria - yet does not
produce long-term adverse effects on the nasal
microbiome.1 Organised by SPIE, the international
society for optics and photonics, SPIE Photonics West is the
largest annual event for optic and photonic technologies and one of
the largest scientific conferences in the world.
These results demonstrate that Steriwave is an
effective, potent, short-acting, and non-selective method of nasal
decolonization, while permitting rapid recovery of the native
microbiome at one week after treatment. The study involved
analyzing nasal swabs from 35 healthy volunteers after being
treated with Ondine's Steriwave® Nasal Photodisinfection
System.
The oral presentation will be delivered by Ondine's
Director of Research and Development, Dr Caetano Sabino, at 9am on
Tuesday, 30 January 2024, as part of the "Photonic Diagnosis,
Monitoring, Prevention, and Treatment of Infections and
Inflammatory Diseases" session.
The "Microbiome Analysis of Photodynamic Nasal
Decolonization" abstract can be
accessed here.
_________
1 The nasal microbiome consists of a
complex community of microorganisms - fungi, parasites, viruses,
and bacteria - that can act in a symbiotic relationship in the
nasal cavity.
**ENDS**
Ondine Biomedical
Inc.
|
|
Carolyn Cross, CEO
|
+001 (604) 665 0555
|
|
|
Singer Capital Markets (Nominated Adviser and Joint
Broker)
|
|
Aubrey Powell, Asha Chotai, Sam
Butcher
|
+44 (0)20 7496 3000
|
|
|
RBC
Capital Markets (Joint Broker)
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20 7653 4000
|
|
|
Vane Percy & Roberts (Media Contact)
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77 1000 5910
|
About SPIE Photonics
West
SPIE Photonics West is the optics and photonics
industry's preeminent annual conference and exhibition and is one
of the largest scientific conferences in the world. Its scope
covers all areas regarding the use of light for scientific and
technological applications. The conference brings together tens of
thousands of researchers, innovators, engineers, and business
leaders from across the globe for an engaging week of research
sharing, collaboration forming, and innovation-inspiring exchanges.
The week will include more than 4,500 technical presentations as
well as showcasing over 1,200 companies in three focused
exhibitions.
About Ondine
Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life science
company innovating in the field of photodisinfection therapies.
Ondine has a pipeline of investigational products, based on its
proprietary photodisinfection platform, in various stages of
development. Ondine's nasal photodisinfection system has a CE
mark in Europe and the UK and is approved in Canada and several
other countries under the name Steriwave®. In the US, it has
been granted Qualified Infectious Disease Product designation and
Fast Track status by the FDA and is currently undergoing clinical
trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical
indications such as chronic sinusitis, ventilator-associated
pneumonia, burns, and other indications.
About Nasal
Photodisinfection
Ondine's Steriwave® Nasal
Photodisinfection System is a patented technology using a
proprietary light-activated antimicrobial (photosensitizer) to
destroy pathogens. The photodisinfection treatment is carried out
by a trained healthcare professional and is an easy to use,
painless, two-step process. The photosensitizer is applied to
each nostril using a nasal swab, followed by illumination of the
area with a specific wavelength of red laser light for less than
five minutes. The light activates the photosensitizer, causing an
oxidative burst that is lethal to all types of pathogens. A key
benefit of this approach, unlike with antibiotics, is that
pathogens do not develop resistance to the therapy.
Nasal decolonization with antibiotics is
already standard practice in many hospitals prior to surgery, as
pathogens in a patient's nasal cavities are a major cause of
surgical site infections (SSIs). Nasal decolonization is
recommended in the 2016 WHO Global guidelines for the
prevention of surgical site infections,[1]
and the Society for Healthcare Epidemiology of America (SHEA)
guidelines, published in May 2023, recommend nasal decolonization
for major surgical procedures.[2]
However, there is a growing need to reduce antibiotic
use and find non-antibiotic methods of nasal decolonization as
resistance rates have been reported as high as 81%.[3]